Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer
The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Abstract
Purpose Transforming growth factor-beta inhibitors may enhance the antitumor activity of gemcitabine with acceptable safety and tolerability. This open-label, multicenter, non-randomized phase 1b study assessed the safety/tolerability, pharmacokinetics, and tumor response of galunisertib plus gemcitabine in Japanese patients with advanced or metastatic pancreatic cancer.Methods During each 28-day cycle, galunisertib 150 mg was administered orally twice daily (300 mg/day) for 14 days, followed by 14 days of rest. Gemcitabine 1000 mg/m 2 was intravenously given on Days 8, 15, and 22. Safety was assessed by the incidence of dose-limiting toxicities (DLTs) in the first cycle and treatment-emergent adverse events (TEAEs). Efficacy was assessed by antitumor activity and changes in carbohydrate antigen 19-9 (CA19-9).Results No DLTs were reported. All 7 enrolled patients had ≥1 TEAE, of which the most common included anorexia, decreased neutrophil count, and decreased white blood cell count. Grade ≥3 TEAEs were observed in 6 patients; 4 patients had Grade ≥3 TEAEs (decreased neutrophil, white blood cell, and lymphocyte count; hypophosphatemia) considered possibly related to study drug(s). The pharmacokinetic profile of galunisertib in combination with gemcitabine was similar to that previously observed for galunisertib alone. The clinical response [complete response (CR), partial response (PR), or stable disease] rate was 42.9%, and the median progression-free survival was 64 days; no CR/PR were achieved.Conclusion Galunisertib plus gemcitabine had an acceptable safety/tolerability profile with evidence of efficacy in Japanese patients with advanced or metastatic pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, various small molecule inhibitors of TGF‐β, including galunisertib (LY2157299) [166, 167, 168], vactosertib (TEW‐7197) [169, 170, 171] and LY3200882 [172], have shown specific antitumor activity.”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [168]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
Self-citationBalaban, E. P., Mangu, P. B., Khorana, A. A., Shah, M. A., Mukherjee, S., Crane, C. H., Javle, M. M., Eads, J. R., Allen, P., Ko, A. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5561 · Cited by 381
Khorana, A. A., Mangu, P. B., Berlin, J., Engebretson, A., Hong, T. S., Maitra, A., Mohile, S. G., Mumber, M., Schulick, R., Shapiro, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5553 · Cited by 366
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O’Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1412 · Cited by 332
Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., Abbruzzese, J. L., & Chiao, P. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0337 · Cited by 323
Darpo, B., Nebout, T., & Sager, P. T. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006286436 · Cited by 319
Rodon, J., Carducci, M. A., Sepulveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 235
Self-citationFujiwara, Y., Nokihara, H., Yamada, Y., Yamamoto, N., Sunami, K., Utsumi, H., Asou, H., Takahashi, O., Ogasawara, K., Gueorguieva, I., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2895-4 · Cited by 102
Self-citationFaivre, S. J., Santoro, A., Kelley, R. K., Merle, P., Gane, E., Douillard, J.-Y., Waldschmidt, D., Mulcahy, M. F., Costentin, C., Minguez, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.lba173 · Cited by 45
Self-citation
Research works printed but not linked: 1
- Schlingensiepen K-H, Stauder G, Bischof A, Egger T, Hafner M, Herrmuth H, Kielmanowicz M, Jachimczak P (2004) TGF-beta2 suppression in pancreatic cancer by the antisense oligonucleotide AP 12009: preclinical efficacy data. Proc Am Assoc Cancer Res 45(suppl):Abstract 2955
Cited by
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies
Cervantes-Villagrana, R. D., Albores-García, D., Cervantes-Villagrana, A. R., & García-Acevez, S. J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0205-z · Cited by 290
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
Ciardiello, D., Elez, E., Tabernero, J., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 265
Metadata
- Authors
- Ikeda, M., Takahashi, H., Kondo, S., Lahn, M. M. F., Ogasawara, K., Benhadji, K. A., Fujii, H., & Ueno, H.
- Affiliations
- National Cancer Center Hospital East (JP)
- National Cancer Center Hospital (JP)
- Johns Hopkins University (US)
- Eli Lilly (United States) (US)
- Eli Lilly (Japan) (JP)
- Corresponding author
- Ikeda, Masafumi
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2017-04-27
- Volume
- 79
- Issue
- 6
- Pages
- 1169-1177
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2608573151
- Cited by
- 51
- References
- 14
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 6 · 2019: 10 · 2018: 6 · 2017: 1
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (US)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- galunisertib, gemcitabine, metastatic pancreatic cancer, locally advanced pancreatic cancer, TGF-β inhibitors, combination chemotherapy, safety and tolerability, pharmacokinetics, dose-limiting toxicity, CA19-9, Japanese patients
- MeSH terms
- Gemcitabine, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Pyrazoles, Quinolines, Biomarkers, Tumor, CA-19-9 Antigen, Disease-Free Survival, Area Under Curve, Maximum Tolerated Dose, Asian People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. https://app.cochat.ai/papers/10.1007/s00280-017-3313-x
- The paper
- Ikeda, M., Takahashi, H., Kondo, S., Lahn, M. M. F., Ogasawara, K., Benhadji, K. A., Fujii, H., & Ueno, H. (2017). Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-017-3313-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.